SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded
interventional trial that will examine the potential benefits and risks of adjunctive
hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic
shock.
It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of
children with poor outcomes, defined as death or severely impaired health-related quality of
life (HRQL), as assessed at 28 days following study enrollment (randomization).
Phase:
Phase 3
Details
Lead Sponsor:
Jerry Zimmerman
Collaborators:
Canadian Critical Care Trials Group Canadian Institutes of Health Research (CIHR) Children's Hospital of Eastern Ontario Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)